Биологическая терапия бронхиальной астмы: настоящее и будущее

Обложка
  • Авторы: Ненашева Н.М1
  • Учреждения:
    1. ФГБОУ ДПО Российская медицинская академия непрерывного профессионального образования Минздрава России
  • Выпуск: Том 18, № 11 (2016)
  • Страницы: 30-38
  • Раздел: Статьи
  • URL: https://ogarev-online.ru/2075-1753/article/view/94556
  • ID: 94556

Цитировать

Полный текст

Аннотация

Данная обзорная статья посвящена настоящим и будущим возможностям применения биологических молекул в лечении бронхиальной астмы. За последние 20 лет произошел прорыв в области биологической терапии тяжелой бронхиальной астмы с помощью молекул моноклональных антител. Три биологических препарата (омализумаб, меполизумаб и реслизумаб) уже одобрены для применения в обычной клинической практике в ряде стран, а омализумаб уже давно и успешно применяется повсеместно, в том числе в нашей стране.

Об авторах

Н. М Ненашева

ФГБОУ ДПО Российская медицинская академия непрерывного профессионального образования Минздрава России

Email: 1444031@gmail.com
д-р мед. наук, проф. каф. клинической аллергологии ФГБОУ ДПО РМАНПО 125993, Россия, Москва, ул. Баррикадная, д. 2/1

Список литературы

  1. 1. GINA 2016 www.ginasthma.org
  2. Chuchalin A.G, Khaltaev N, Аntonov N. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int J COPD 2014; 9: 963-74.
  3. Национальная программа «Бронхиальная астма у детей. Стратегия лечения и профилактика». IV изд. М., 2012.
  4. Bousqet J, Mantzouranis E, Cruz A.A et al. Uniform definition of asthma severity, control and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol 2010; 126: 926-38.
  5. Chung K.F, Wenzel S, Brozek J et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43: 343-73.
  6. Locksley R.M. Asthma and allergic inflammation. Cell 2010; 140 (6): 777-83.
  7. Li B.W, Hendriks R.W: Group 2 innate lymphoid cells in lung inflammation. Immunology 2013; 140 (3): 281-7.
  8. Kita H. Eosinophils: multifunctional and distinctive properties. Int Arch Allergy Immunol 2013; 161 (Suppl. 2): 3-9.
  9. Bousquet J, Chanez P, Lacoste J.Y et al. Eosinophilic inflammation in asthma. N Engl J Med 1990; 323: 1033-9.
  10. Blanchard C, Rothenberg M.E. Biology of the eosinophil. Adv Immunol 2009; 101: 81-121.
  11. Melo R.C, Liu L, Xenakis J.J et al. Eosinophil - derived cytokines in health and disease: unraveling novel mechanisms of selective secretion. Allergy 2013; 68 (3): 274-84.
  12. Fahy J.V. Eosinophilic and neutrophilic inflammation in asthma: insights from clinical studies. Proc Am Thorac Soc 2009; 6 (3): 256-9.
  13. Duncan C.J, Lawrie A, Blaylock M.G et al. Reduced eosinophil apoptosis in induced sputum correlates with asthma severity. Eur Respir J 2003; 22: 484-90.
  14. Kupczyk M, ten Brinke A, Sterk P et al. Frequent exacerbators - a distinct phenotype of severe asthma. Clin Experim Allergy 2013; 44: 212-21.
  15. Schleich F.N, Manise M, Sele J et al. Distribution of sputum cellular phenotype in a large asthma cohort: predicting factors for eosinophilic vs neutrophilic inflammation. BMC Pulm Med 2013; 13: 11.
  16. Moore W.C, Meyers D.A, Wenzel S.E et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010; 181: 315-23.
  17. Haldar P, Pavord I.D, Shaw D.E et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008; 178: 218-24.
  18. Siroux V, Basagana X, Boudier A et al. Identifying adult asthma phenotypes using a clustering approach. Eur Respir J 2011; 38: 310-7.
  19. Chung K.F, Bel E.H, Wenzel S.E. Difficult - to - Treat Severe Asthma. Eur Respir Soc Monograph 2011; 51: 310.
  20. Shaw D, Sousa A, Fowler S et al. Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. Eur Respir J 2015; 46: 1308-21.
  21. Trevor J.L, Deshane J.S. Refractory asthma: mechanisms, targets, and therapy. Allergy 2014; 69: 817-27.
  22. Kuhl K, Hanania N.A. Targeting IgE in asthma. Curr Opin Pulm Med 2012; 18: 1-5.
  23. Walker S, Monteil M, Phelan K et al. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev 2006; 2: CD003559.
  24. Rodrigo G.J, Neffen H, Castro-Rodriguez J.A. Efficacy and safety of subcutaneous omalizumab vs placebo as add - on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest 2011; 139 (1): 28-35.
  25. Normansell R, Walker S, Milan S et al. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev 2014; 1: CD003559.
  26. Brusselle G, Michils A, Louis R et al. “Real - life” effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study. Resp Med 2009; 103: 1633-42.
  27. Braunsthl G.J, Chlumsky J, Peachey G, Chen C.W. Reduction in oral corticosteroid use in patients receiving omalizumab for allergic asthma in the real - world setting. Allergy Asthma Clin Immunol 2013; 9: 47.
  28. Чучалин А.Г., Пашкова Т.Л., Осипова Г.Л., Сучкова Ю.Б. Оценка эффективности и безопасности омализумаба в комплексной терапии больных с тяжелой неконтролируемой атопической бронхиальной астмой в течение 12 месяцев наблюдения. Пульмонология. 2009; 3: 75-80.
  29. Salvin R.G, Feroli C, Tannenbaum S.J et al. Asthma symptom re - emergence after omalizumab withdrawal correlates well with increasing pharmacokinetic concentations. J Allergy Clin Immunol 2009; 123: 107-13.
  30. Molimard M, Mala L, Bourdeix I, Le Gros V. Observation study in severe asthmatic patients after discontinuation of omalizumab for good asthma control. Respir Med 2014; 108: 571-6.
  31. Bousquet J, Rabe K, Humbert M et al. Predicting and evaluating responce to omalizumab in patients with severe allergic asthma. Respir Med 2007; 101: 1483-92.
  32. Wahn U, Martin C, Freeman P et al. Relationship between pretreatment specific IgE and the responce to omalizumab therapy. Allergy 2009; 64: 1780-7.
  33. Hanania N.A, Wenzel S, Rosen K et al. Exploring the effect of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 2013; 187: 804-11.
  34. Massanari M, Holgate S.T, Busse W.W et al. Effect of omalizumab on peripheral blood eosinophilia in allergic asthma. Respir Med 2010; 104 (2): 188-96.
  35. Djukanović R, Wilson S.J, Kraft M et al. Effects of treatment with anti - immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004; 170 (6): 583-93.
  36. Инструкция к применению препарата Ксолар.
  37. Luijk B, Lindemans C, Kanters D et al. Gradual increase in priming of human eosinophils during extravasation from peripheral blood to the airways in response to allergen challenge. J Allergy Clin Immunol 2005; 115: 997-1003
  38. Kouro T, Takatsu T. IL-5- and eosinophil - mediated inflammation: from discovery to therapy. Int Immunol 2009; 21 (12): 1303-9.
  39. Flood-Page P, Menzies-Gow A, Phipps S et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepitelial basement membrance of mild atopic astmatics. J Clin Invest 2003; 112: 1029-36.
  40. Menzies-Gow A, Flood-Page P, Sehmi R et al. Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asyhmatics. J Allergy Clin Immunol 2003; 111: 714-9.
  41. Leckie M.J, ten Brinke A, Khan J et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airways hyperresponsiveness, and the late asthmatic responce. Lancet 2000; 356: 2144-8.
  42. Nair P, Pizzichini M, Kjarsgaard M et al. Mepolizumab for prednison - dependent asthma with sputum eosinophilia. N Engl J Med 2009; 360: 985-93.
  43. Haldar P, Brighting C, Hargardon B et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360: 973-84.
  44. Pavord I.D, Korn S, Howarth P et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double - blind, placebo - controlled trial. Lancet 2012; 380: 651-9.
  45. Ortega H.G, Liu M.C, Pavord I.D et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014; 371: 1198-207.
  46. Bel E.H, Wenzel S.E, Thompson P.J et al. Oral glucocorticoid - sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014; 371: 1189-97.
  47. Haldar P, Brighting C, Singapuri A et al. Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow - up analysis. J Allergy Clin Immunol 2014; 133: 921-3.
  48. Castro M, Mathur S, Hargreave F et al. Reslizumab for poorlycontrolled, eosinophilic asthma: a randomized, placebo - controlledstudy. Am J Respir Crit Care Med 2011; 184: 1125-32.
  49. Castro M, Zangrilli J, Wechlser M.E et al. Reslizumab foe inadequately controlled asthma with elevated blood eosinophil counts: results from two multicenter, parallel, double - blind, randomized, placebo - controlled, phase 3 trials. Lancet Respir Med 2015; 3: 355-66.
  50. Kolbeck R, Kozhich A, Koike M et al. Medi-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody - dependent cell mediated cytotoxicity function. J Allergy Clin Immunol 2010; 125 (1): 1344-53.
  51. Busse W.W, Katial R, Gossage D et al. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol 2010; 125: 1237-44.
  52. Laviolette M, Gossage D.L, Gaureau G et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol 2013; 132: 1086-96.
  53. Castro M, Wenzel S.E, Bleecker E.R et al. Benralizumab, an anti - interleukin 5 receptor a monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose - ranging study. Lancet Respir Med 2014; 2 (11): 879-90.
  54. Oh C.K, Geba G.P, Molfino N et al. Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma. Eur Respir Rev 2010; 19: 46-54.
  55. Jia G, Erickson R.W, Choy D et al. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients J Allergy Clin Immunol 2012; 130: 647-54.
  56. Corren J, Lemanske R.F, Hanania N.A et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011; 365 (12): 1088-98.
  57. Scheerens H, Arron J.R, Su Z et al. Predictive and pharmacodynamic biomarkers of interleukin-13 blockade: effect of lebrikizumab on late phase asthmatic response to allergen challenge. J Allergy Clin Immunol 2011; 127 (Suppl. 2): AB164.
  58. Hanania N.A, Noonan M.J, Corren J et al. Efficacy and safety of lebrikizumab in severe uncontrolled asthma: results from the lute and verse phase II randomized, double - blind, placebo - controlled trials. J Allergy Clin Immunol 2014; 133 (2): AB402.
  59. Blanchard C, Mishra A, Sito-Hakel H et al. Inhibition of human interleukin-13-induced respiratory and esophageal inflammation by antihuman interleukin-13 antibody (CAT-354). Clin Exp Allergy 2005; 35: 1096-103.
  60. Piper E, Brightling C, Niven R et al. A phase II placebo - controlled study of tralocinumab in moderate - to - severe asthma. Eur Respir J 2013; 41: 330-8.
  61. Brightling C, Chanez P, Leigh R, O’Byrne P et al. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double - blind, placebo - controlled, phase 2b trial. Lancet Respir Med 2015; 3 (9): 692-701.
  62. Wenzel S, Ford L, Pearlman D et al. Dupilumab in Persistent Asthma with Elevated Eosinophil Levels. N Engl J Med 2013; 368 (26): 2455-66.
  63. Wenzel S, Castro M, Corren J et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium - to - high - dose inhaled corticosteroids plus a long - acting b2 agonist: a randomised double - blind placebo - controlled pivotal phase 2b dose - ranging trial. Lancet 2016; 388: 31-44.
  64. Wang Y.H, Wills-Karp M. The potential role of interleukin-17 in severe asthma. Curr Allergy Asthma Rep 2011; 11 (5): 388-94.
  65. Kudo M, Melton A.C, Chen C et al. IL-17A produced by alphabeta T cells drives airway hyperresponsiveness in mice and enhances mouse and human airway smooth muscle contraction. Nat Med 2012; 18 (4): 547-54.
  66. Min Xie, Wenzel S.E. A global perspective in asthma: from phenotype to endotype. Chinese Med J 2013; 126 (1): 166-74.
  67. Chesne J, Braza F, Mahay G et al. IL-17 in Severe Asthma. Where Do We Stand? Am J Respir and Crit Care Med 2014; 190 (10): 1094-101.
  68. Busse W.W, Holgate S, Kerwin E et al. Randomized, double - blinde, placebo - controlled study of brodalumab, a human anti-IL17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med 2013; 188: 1294-302.
  69. Newcomb D.C, Peebles R.S Jr. Th17-mediated inflammation in asthma. Curr Opin Immunol 2013; 25: 755-60.
  70. Morishima Y, Ano S, Ichii Y et al. Th17-associated cytokines as a therapeutic target for steroid - insensitive asthma. Clin Dev Immunol 2013; 609: 395.
  71. Mc Cracken J, Tripple J, Calhoun W.J. Biologic therapy in the management of asthma. Allergy Clin Immunol 2016; 16 (4): 375-82.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО "Консилиум Медикум", 2016

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).